

## Principales publications

La liste ci-dessous présente les **29 publications** des membres de l'unité de biostatistique en tant que premier ou dernier auteur par catégorie entre 1996 et 2009 :

- **Tests diagnostiques (4 publications)**
- **Essais précoces: phases I et II (9 publications)**
- **Analyses intermédiaires (2 publications)**
- **Facteurs pronostiques (2 publications)**
- **Surveillances des cancers (2 publication)**
- **Epidémiologie (2 publications)**
- **Evaluation des pratiques (4 publications)**
- **Lettres à l'éditeur (4 publications)**

- **Tests diagnostiques**

1. **Kramar, A.**, D. Faraggi, A. Fortune and B. Reiser (2001). "mROC: a computer program for combining tumour markers in predicting disease states." Comput Methods Programs Biomed **66**(2-3): 199-207.
2. Faraggi, D. and **A. Kramar** (2000). "Methodological issues associated with tumor marker development. Biostatistical aspects." Urol Oncol **5**(5): 211-213.
3. **Kramar, A.**, D. Faraggi, M. Ychou, B. Reiser and J. Grenier (1999). "[Generalized ROC criteria in the evaluation of several tumor markers]." Rev Epidemiol Sante Publique **47**(4): 376-83.
4. Kwiatkowski, F., F. Gachon, S. Charrier, H. Sancho-Garnier and **A. Kramar** (1999). "[Decision making in biology: ROC analysis]." Bull Cancer **86**(9): 787-9.

### Essais précoces: phases I et II

1. Paoletti, X., and **A. Kramar**. "A comparison of model choices for the Continual Reassessment Method in Phase I cancer trials". Stats Med 2009 (accepté)
2. Houédé, N., P.F. Thall, H. Nguyen, X. Paoletti, and **A. Kramar**. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials". Biometrics 2009, (accepté)
3. **Kramar, A.**, N. Houédé and X. Paoletti (2007). "np1: a computer program for dose escalation strategies in phase I clinical trials." Comput Methods Programs Biomed **88**(1): 8-17.
4. Tubert-Bitter, P., A. Letierce, D.A. Bloch and **A. Kramar** (2005). "A nonparametric comparison of the effectiveness of treatments: a multivariate toxicity-penalized approach." J Biopharm Stat **15**(1): 129-42.
5. Culine, S., G. Romieu, M. Fabbro, C. Becht, D. Cupissol, C. Guillemare, J. P. Bleuse, V. Lotz and **S. Gourgou** (2004). "Reducing the time interval between cycles using standard doses of docetaxel and lenogastim support: a feasibility study." Cancer **101**(1): 178-82.
6. Ychou, M., T. Conroy, J. F. Seitz, **S. Gourgou**, A. Hua, D. Mery-Mignard and **A. Kramar** (2003). "An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors." Ann Oncol **14**(3): 481-9.
7. **Kramar, A.**, A. Lebecq and E. Candalh (1999). "Continual reassessment methods in phase I trials of the combination of two drugs in oncology." Stat Med **18**(14): 1849-64.
8. **Kramar, A.**, D. Potvin and C. Hill (1996). "Multistage designs for phase II clinical trials: statistical issues in cancer research." Br J Cancer **74**(8): 1317-20.
9. **Kramar, A.**, D. Potvin and C. Hill (1996). "[Research design for patient selection in clinical trials phase II]." Rev Epidemiol Sante Publique **44**(4): 364-71.

- **Analyses intermédiaires**

1. **Kramar, A.** and X. Paoletti (2007). "[Interim analyses.]" Bull Cancer **94**(11): 965-74.
2. **Kramar A.** and **C. Bascoul-Mollevi**. Early stopping rules in clinical trials based on sequential monitoring of serious adverse events. Medical Decision Making. (sous presse)

- **Facteurs pronostiques**

1. Kwiatkowski, F., K. Slim, P. Verrelle, E. Chamorey and **A. Kramar** (2007). "[Propensity score: interest and limits]." Bull Cancer **94**(7): 680-6.
2. Azria, D., F. Bibeau, N. Barbier, A. Zouhair, C. Lemanski, P. Rouanet, M. Ychou, P. Senesse, M. Ozsahin, A. Pelegrin, J. B. Dubois and **S. Thezenas** (2005). "Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer." BMC Cancer **5**(1): 62.

- **Surveillances des cancers**

1. Ataman, O. U., A. Barrett, T. Filleron and **A. Kramar** (2006). "Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO." Radiother Oncol **78**(1): 95-100.
2. Filleron T, Barrett A, Ataman O, **Kramar A**. Planning post-therapeutic oncology surveillance visits based on individual risk. Medical Decision Making. (sous presse)

- **Epidémiologie**

1. **Gourgou, S.**, F. Dedieu and H. Sancho-Garnier (2002). "Lower limb venous insufficiency and tobacco smoking: a case-control study." Am J Epidemiol **155**(11): 1007-15.
2. **Bascoul-Mollevi, C.**, **S. Gourgou-Bourgade** and **A. Kramar** (2005). "Two-part statistics with paired data." Stat Med **24**(9): 1435-48.

- **Evaluation des pratiques**

1. Mathoulin-Pelissier, S., **S. Gourgou-Bourgade**, F. Bonnetain and **A. Kramar** (2008). "Survival end point reporting in randomized cancer clinical trials: a review of major journals." J Clin Oncol **26**(22): 3721-6.
2. **Thezenas, S.**, J. Duffour, S. Culine and **A. Kramar** (2004). "Five-year change in statistical designs of phase II trials published in leading cancer journals." Eur J Cancer **40**(8): 1244-9.
3. **Kramar, A.**, T. Kachmar and J. M. Hannoun-Levi (2003). "[Increasing the quality of clinical trials in oncology: an important challenge]." Bull Cancer **90**(10): 919-923.
4. Droz, J. P., S. Culine, P. Biron and **A. Kramar** (1996). "High-dose chemotherapy in germ-cell tumors." Ann Oncol **7**(10): 997-1003.

- **Lettres à l'éditeur**

1. **Kramar, A.**, F. Bonnetain and S. Mathoulin-Pelissier (2008). "[Role of the methodology in cluster randomized trials]." Bull Cancer **95**(12): 1141-2.
2. **Kramar, A.**, **S. Gourgou-Bourgade** and M. Ychou (2005). "Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan." J Clin Oncol **23**(3): 650.
3. Evrard, S., S. Mathoulin-Pelissier and **A. Kramar** (2003). "[Laparoscopy treatment of colon cancer: ducking is no fair play!]." Bull Cancer **90**(2): 188-9.
4. Evrard, S., S. Mathoulin-Pelissier and **A. Kramar** (2003). "Open versus laparoscopy-assisted colectomy." Lancet **361**(9351): 73; author reply 75-6.